syndecan-1蛋白在胃癌中的表達及其意義_《中國普外基礎與臨床雜志》

作者：

譚明 ¹ , 戴春 ¹ , 丁永斌 ² , 夏建國 ²

1.江蘇省揚中市人民醫院普外科(揚中212200);;
2.南京醫科大學第一附屬醫院胃腸外科（南京 210029）;

關鍵詞：

胃癌 syndecan-1蛋白淋巴結轉移

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的研究syndecan-1蛋白在胃癌及正常胃黏膜組織中的表達，探討其與胃癌臨床病理特征的關系。方法應用免疫組化ABC法檢測60例胃癌及正常胃黏膜組織中syndecan-1蛋白的表達水平。結果 60例正常胃黏膜組織中均有syndecan-1蛋白表達，但胃癌組織中僅有10例（16.67%）呈陽性表達，正常胃黏膜組織中syndecan-1蛋白表達陽性率明顯高于胃癌組織（χ2=65.88，P＜0.05）。syndecan-1蛋白的表達與腫瘤大小、浸潤深度、淋巴結轉移及TNM分期有關(P＜0.05)，其中無淋巴結轉移的胃癌組織中syndecan-1蛋白表達陽性率明顯高于有淋巴結轉移者（χ2=18.62，P＜0.05）；與胃癌患者的年齡和腫瘤部位無關(P gt;0.05)。結論胃癌組織中syndecan-1蛋白低表達，并與胃癌分期和淋巴結轉移有關。

引用本文： 譚明,戴春,丁永斌,夏建國. syndecan-1蛋白在胃癌中的表達及其意義. 中國普外基礎與臨床雜志, 2008, 15(12): 910-913. doi: 復制

1.	Bernfield M, Kokenyesi R, Kato M, et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans [Ｊ]. Annu Rev Cell Biol, 1992; 8∶ 365.
2.	史偉峰, 陳同鈺, 張學光. CD138分子生物學特性與腫瘤關系的研究進展 [Ｊ]. 國外醫學·臨床生物化學與檢驗學分冊, 2002; 23(1)∶ 39.
3.	Yoo CH, Noh SH, Kim YI, et al. Comparison of prognostic significance of nodal staging between old (4th edition) and new (5th edition) UICC TNM classification for gastric carcinoma.International Union Against Cancer [Ｊ]. World J Surg, 1999; 23(5)∶ 492.
4.	Kaushal GP, Xiong X, Athoto AB, et al. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9 [Ｊ]. Br J Haematol, 1999; 104(2)∶ 365.
5.	Saqi A, Yun SS, Yu GH, et al. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas [Ｊ]. Diagn Cytopathol, 2005; 33(2)∶ 65.
6.	Mitselou A, Ioachim E, Peschos D, et al. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies [Ｊ]. Exp Oncol, 2007; 29(1)∶ 54.
7.	馮云路，肖毅，錢家鳴，等. syndecan-1在結直腸癌中的表達及意義 [Ｊ]. 中國普外基礎與臨床雜志, 2007; 14(3)∶ 320.
8.	Huang MF, Zhu YQ, Chen ZF, et al. Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer [Ｊ]. World J Gastroenterol, 2005; 11(19)∶ 2975.
9.	席銀雪，寧鑫，陳潔，等. Syndecan-1在胃黏膜癌變不同階段組織中的表達及意義 [Ｊ]. 中華腫瘤雜志, 2007; 29(3)∶ 193.
10.	Watari J, Saitoh Y, Fujiya M, et al. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype [Ｊ]. J Gastroenterol, 2004; 39(2)∶ 104.
11.	Hayashi K, Hayashi M, Jalkanen M, et al. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study [Ｊ]. J Histochem Cytochem, 1987; 35(10)∶ 1079.
12.	Hirabayashi K, Numa F, Suminami Y, et al. Altered proliferative and metastatic potential associated with increased expression of syndecan-1 [Ｊ]. Tumour Biol, 1998; 19(6)∶ 454.
13.	茹國慶，趙仲生，湯琪樂，等. Syndecan-1和乙酰肝素酶mRNA表達與胃癌轉移和預后的關系 [Ｊ]. 中華外科雜志, 2006; 44(15)∶1062.
14.	Peretti T, Waisberg J, Mader AM, et al. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma [Ｊ]. Eur J Gastroenterol Hepatol, 2008; 20(8)∶ 756.
15.	Roh YH, Kim YH, Choi HJ, et al. Syndecan-1 expression in gallbladder cancer and its prognostic significance [Ｊ]. Eur Surg Res, 2008; 41(2)∶ 245.
16.	王學浩，成峰，錢建民，等. syndecan-1蛋白的表達與肝細胞肝癌惡性表型的研究 [Ｊ]. 中國普外基礎與臨床雜志, 2001; 8(4)∶ 239.
17.	Wiksten JP, Lundin J, Nordling S, et al. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer [Ｊ]. Oncology, 2005; 68(4-6)∶ 306.
18.	Wiksten JP, Lundin J, Nordling S, et al. A prognostic value of syndecan-1 in gastric cancer [Ｊ]. Anticancer Res, 2000; 20(6D)∶ 4905.
19.	Oguri K, Okayama M. Can syndecan-1 become a prognostic factor in solid tumors? [Ｊ]. J Gastroenterol, 2004; 39(2)∶ 197.

1. Bernfield M, Kokenyesi R, Kato M, et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans [Ｊ]. Annu Rev Cell Biol, 1992; 8∶ 365.
2. 史偉峰, 陳同鈺, 張學光. CD138分子生物學特性與腫瘤關系的研究進展 [Ｊ]. 國外醫學·臨床生物化學與檢驗學分冊, 2002; 23(1)∶ 39.
3. Yoo CH, Noh SH, Kim YI, et al. Comparison of prognostic significance of nodal staging between old (4th edition) and new (5th edition) UICC TNM classification for gastric carcinoma.International Union Against Cancer [Ｊ]. World J Surg, 1999; 23(5)∶ 492.
4. Kaushal GP, Xiong X, Athoto AB, et al. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9 [Ｊ]. Br J Haematol, 1999; 104(2)∶ 365.
5. Saqi A, Yun SS, Yu GH, et al. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas [Ｊ]. Diagn Cytopathol, 2005; 33(2)∶ 65.
6. Mitselou A, Ioachim E, Peschos D, et al. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies [Ｊ]. Exp Oncol, 2007; 29(1)∶ 54.
7. 馮云路，肖毅，錢家鳴，等. syndecan-1在結直腸癌中的表達及意義 [Ｊ]. 中國普外基礎與臨床雜志, 2007; 14(3)∶ 320.
8. Huang MF, Zhu YQ, Chen ZF, et al. Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer [Ｊ]. World J Gastroenterol, 2005; 11(19)∶ 2975.
9. 席銀雪，寧鑫，陳潔，等. Syndecan-1在胃黏膜癌變不同階段組織中的表達及意義 [Ｊ]. 中華腫瘤雜志, 2007; 29(3)∶ 193.
10. Watari J, Saitoh Y, Fujiya M, et al. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype [Ｊ]. J Gastroenterol, 2004; 39(2)∶ 104.
11. Hayashi K, Hayashi M, Jalkanen M, et al. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study [Ｊ]. J Histochem Cytochem, 1987; 35(10)∶ 1079.
12. Hirabayashi K, Numa F, Suminami Y, et al. Altered proliferative and metastatic potential associated with increased expression of syndecan-1 [Ｊ]. Tumour Biol, 1998; 19(6)∶ 454.
13. 茹國慶，趙仲生，湯琪樂，等. Syndecan-1和乙酰肝素酶mRNA表達與胃癌轉移和預后的關系 [Ｊ]. 中華外科雜志, 2006; 44(15)∶1062.
14. Peretti T, Waisberg J, Mader AM, et al. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma [Ｊ]. Eur J Gastroenterol Hepatol, 2008; 20(8)∶ 756.
15. Roh YH, Kim YH, Choi HJ, et al. Syndecan-1 expression in gallbladder cancer and its prognostic significance [Ｊ]. Eur Surg Res, 2008; 41(2)∶ 245.
16. 王學浩，成峰，錢建民，等. syndecan-1蛋白的表達與肝細胞肝癌惡性表型的研究 [Ｊ]. 中國普外基礎與臨床雜志, 2001; 8(4)∶ 239.
17. Wiksten JP, Lundin J, Nordling S, et al. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer [Ｊ]. Oncology, 2005; 68(4-6)∶ 306.
18. Wiksten JP, Lundin J, Nordling S, et al. A prognostic value of syndecan-1 in gastric cancer [Ｊ]. Anticancer Res, 2000; 20(6D)∶ 4905.
19. Oguri K, Okayama M. Can syndecan-1 become a prognostic factor in solid tumors? [Ｊ]. J Gastroenterol, 2004; 39(2)∶ 197.

《中國普外基礎與臨床雜志》

syndecan-1蛋白在胃癌中的表達及其意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

syndecan-1蛋白在胃癌中的表達及其意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料